PFF Help Center(844) 825-5733

Facebook this link will open a new tab. Twitter this link will open a new tab. LinkedIn this link will open a new tab. YouTube this link will open a new tab. Instagram this link will open a new tab.

this link will open a new tab. this link will open a new tab. Join the PFF Registry Donate this link will open a new tab. Shop PFF this link will open a new tab.

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

PFF Help Center(844) 825-5733

Facebook this link will open a new tab. Twitter this link will open a new tab. LinkedIn this link will open a new tab. YouTube this link will open a new tab. Instagram this link will open a new tab.

this link will open a new tab. this link will open a new tab. Join the PFF Registry Donate this link will open a new tab. Shop PFF this link will open a new tab.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Donate this link will open a new tab.

Drug

Tulisokibart (MK-7240/PRA023)

Status:

Phase 2

Condition:

Systemic Sclerosis ILD

Intervention Type:

Subcutaneous (SC) Injection

Funder Type:

Industry

Drug Details

Tulisokibart (MK-7240/PRA023) is an investigational humanized monoclonal antibody directed to tumor necrosis factor (TNF)-like ligand 1A (TL1A).

Study Purpose

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.

This drug has no clinical trials actively recruiting patients at this time.